Hematological Malignancy, Solid Tumor
Conditions
Keywords
Molecular profiling, Genomic alteration, Advanced cancer
Brief summary
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.
Detailed description
The need to 'personalize' cancer therapy has been recognized, with specific biomarkers which will be used to direct targeted agents only to those patients deemed most likely to respond. This personalized cancer medicine requires two critical steps: first, a comprehensive assessment of the biological characteristics of tumors from each individual, and second, validated biomarkers to identify the subgroups of patients who are most likely to benefit from a given therapy and the next-generation sequencing provides unprecedented opportunities to draw a comprehensive picture of genetic aberrations involve in immunotherapy sensitivity and ultimately enable individualized treatment. The main objective of this study is to use next generation sequencing technologies to identify actionable molecular alterations in cancer patients with advanced disease included in the study. This study will provide a fully integrated view of the molecular profile of the tumor for each patient included in the study. Such tumor profile will be used by clinicians to tailor therapies of patients in specific early phase clinical trials.
Interventions
PROCEDURENewly obtained biopsy and Blood samples collection
For each patient: * Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling * Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient. Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first. All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report.
Sponsors
Institut Bergonié
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years, 2. Histology: solid malignant tumor or hematological malignancy, 3. Deleted MSA9 4. Deleted MSA9, 5. Deleted MSA9, 6. Deleted MSA9, 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code), 8. Voluntary signed and dated written informed consent prior to any study specific procedure.
Exclusion criteria
1. Deleted MSA9 2. Deleted MSA9 3. Deleted MSA9 4. Deleted MSA9 5. Deleted MSA9 6. Deleted MSA9 7. Deleted MSA9 8. Deleted MSA9 9. Individuals deprived of liberty or placed under guardianship 10. Pregnant or breast feeding women, 11. Previous enrolment in the present study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients presenting at least one genomic alteration | 1 month | The proportion of patients with advanced cancer presenting at least one genomic alteration will be described in the NGS population and reported using the proportion. The 95% two-sided confidence limits (95%CI) will be provided for the calculated rate (binomial law). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| - Utilization rates of molecular profiling information (including utilization of information for standard regimens or clinical trials of molecularly targeted therapies) | Utilization rates of molecular profiling information will be evaluated until the date of death from any cause, assessed up to 36 months | Utilization rates of molecular profiling information (including utilization of information for standard regimens or clinical trials of molecularly targeted therapies. For a patient with NGS results available, utilization of molecular profiling information is defined as : * Inclusion in a clinical trial assessing a drug matched with the genetic profile * Treatment with an approved drug matched with the genetic profile |
| Rate of molecular screening failure | Molecular screening failure will be assessed at 1 month | Rate of molecular screening failure. Molecular screening failure is defined as the impossibility to provide genetic profiling because as a result of inadequate tissue or DNA quantity or quality. |
| Safety of biopsies procedures (when applicable) graded according to NCI-CTC v4.0. | Safety will be assessed 1 month after biopsy | Safety of biopsies procedures (when applicable) graded according to NCI-CTC v4.0. |
Countries
France
Contacts
Primary ContactAntoine ITALIANO, MD, PhD
Backup ContactSimone MATHOULIN-PELISSIER, MD, PhD
Outcome results
None listed